focus -WSS

focus

author：explore 2025-10-02 05:38:26 - browse：15

green electrocardiogram scan. -- health tech coverage from STAT — Adobe

As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people who are affected.

The algorithm, which is part of software developed by Viz.ai, earlier this month received clearance from the Food and Drug Administration. The tool, called Viz HCM, looks at 12-lead electrocardiograms collected during routine care and flags suspected cases of hypertrophic cardiomyopathy, or HCM, for further evaluation. As part of a multi-year agreement between the companies, BMS — whose drug, Camzyos, is used to treat HCM — provided funding and scientific input for the development of the algorithm.

“BMS has a vested interest in finding more patients with HCM,” said Matthew Martinez, a cardiologist who leads Viz.ai’s HCM medical advisory board. “Why? Because they’re so philanthropic? No, they want to sell more drugs. They want to help more people by identifying more people.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： BMI, flaws aside, is found to be useful estimate of body fat in youth

hotspot

WSS

Innovation in antibiotics is ailing. 'Brain drain' may kill it

What to do when lifesaving products contribute to climate change

Intellia reports positive results for its CRISPR

Cord blood banking comes at a high cost to babies

At ASCO, AstraZeneca reports strong data for breast cancer drug

Despite FDA concern, risk that CAR

focus

focus

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

UnitedHealth’s Optum accused of antitrust violations in California

Medical records are filled with copy

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Virginia high school admissions case could be legal follow

Takeda, Janssen join wearable maker to measure scratching

Bright Health sells Medicare Advantage business to Molina

Disappointing trial forces Pfizer to pivot on obesity medicine plans

In age of alternative facts, a scholarly course on calling out crap

Pediatric cancer treatments threatened by a new FDA policy

leisure time

What to do when lifesaving products contribute to climate change

Mayo Clinic plans $5B tech

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

U.K. Biobank has 500,000 peoples' genome sequences available

Despite FDA concern, risk that CAR

How to pay for weight loss drugs and save Medicare

knowledge

focus

hotspot

hotspot